Chinese Academy of Sciences
Clinical Trials
63
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (48 trials with phase data)• Click on a phase to view related trials
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Conditions
- Hepatocellular Carcinoma (HCC)Microvascular Invasion (MVI)
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT07170345
- Locations
- 🇨🇳
Meng Chao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China
🇨🇳Zhujiang Hospital, Guangzhou, Guangdong, China
Research on Identifying Critical Surgical Anatomy in Cholecystectomy Videos Based on Deep Learning
- Conditions
- CholecystectomySurgical Video Identification
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT07158372
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Beijing Anzhen Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing Luhe Hospital, Capital Medical University, Beijing, China
Protein Supplementation Intervention on Body Weight
- Conditions
- ObesityWeight LossProtein Supplementation
- Interventions
- Behavioral: Calorie-restricted balanced dietBehavioral: General lifestyle and nutritional educationDietary Supplement: Dietary protein supplementation
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 140
- Registration Number
- NCT06989203
- Locations
- 🇨🇳
Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
Probiotic Intervention on Body Weight
- Conditions
- ObesityHomeostasisWeight LossProbiotic Intervention
- Interventions
- Behavioral: Energy-restricted nutritional and lifestyle interventionBehavioral: General lifestyle and nutritional educationDietary Supplement: PlaceboDietary Supplement: Probiotic
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 140
- Registration Number
- NCT06989177
- Locations
- 🇨🇳
Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- Conditions
- Gastric CancerImagePathology
- Interventions
- Drug: Neoadjuvant Chemotherapy
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT06035250
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
🇨🇳Peking University Cancer Hospital & Institute, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
News
Chinese Scientists Develop "Nano-Tagging Robot" for Enhanced Cancer Immunotherapy
Chinese researchers led by Han Shuo at the Chinese Academy of Sciences have developed an engineered nanozyme that functions as a "nano-tagging robot" to precisely identify cancer cells for immunotherapy.
Novel Selenium-Enhanced Exosome Therapy Shows Promise for Traumatic CNS Injuries
Researchers from the Chinese Academy of Sciences developed SeNExo, a novel therapeutic agent combining neural stem cell-derived exosomes with ultrasmall nano-selenium particles for treating traumatic brain and spinal cord injuries.
Hydrogels Emerge as Next-Generation Platform for Precision Cancer Drug Delivery
A comprehensive bibliometric analysis of 4,108 publications reveals hydrogels as a rapidly growing field in cancer drug delivery, with annual publications exceeding 613 in 2024.
Novel Bispecific Antibody Shows Promise for Autoimmune Disease Treatment in Preclinical Studies
Researchers at NYU Langone Health developed a bispecific antibody called BiTS that targets both T cell receptors and LAG-3 checkpoints to selectively suppress autoimmune T cells.
China's Aphranel MagiCCrystal CaHA Filler Receives Global Regulatory Approvals, Setting New Standards in Regenerative Aesthetics
Aphranel MagiCCrystal, developed by Shanghai Moyom Biotechnology, has become China's first Class III calcium hydroxylapatite (CaHA) microsphere-based dermal filler to receive NMPA certification.
Novel Digital Cognitive Training Shows Promise for Coronary Heart Disease Patients in Clinical Trial
A groundbreaking clinical trial is evaluating a cloud-based cognitive training app for coronary heart disease patients, featuring adaptive algorithms and classic psychological paradigms.
Oncolytic Virus Ad-TD-nsIL12 Shows Promise in Glioblastoma Phase I Trial
A Phase I trial of Ad-TD-nsIL12, an oncolytic virus, demonstrated safety and efficacy in recurrent glioblastoma patients.